Company intelligence / Profile preview
Owl Therapeutics
San Antonio, Texas, United Statesowltherapeutics.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Phase 2
01
Overview
Owl Therapeutics’ lead candidate, OWL-1410, is a small molecule therapeutic with an open US IND application and Fast Track designation from the FDA for moderate/severe TBI. The company uses proprietary blood-based biomarkers via partnership with Gryphon Bio to enrich clinical trials. Several earlier programs have been discontinued. No published Phase 2/3 results yet; Phase 2 investment sought as of late 2024.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Gryphon Bio
Beyond the preview
Go deeper on Owl Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Owl Therapeutics.